Heavy-light chain mispairing is one of the major concerns for producing bispecific antibodies. bYlok™ technology is a design engineering approach that solves this whist retaining molecule's closer-to-nature structure and simplified downstream purification.
You may also be interested in:
Expression Technologies
Bispecific Antibody
Cell Line Development
Mammalian Expression Technologies
GS Gene Expression System®
GS Xceed® Gene Expression System
GS piggyBac® Transposon System
bYlok™ Bispecific Antibodies Technology
GSquad® Vectors
Author(s):
Lisa Prendergast, Ph.D.
Associate Director, Expression System Sciences
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
White paper
Innovations in linking rational design and material-sparing strategies for enabled intermediates and...
Did you catch our insightful webinar on Linking rational design and material-sparing strategies for...
Capsule services
Webinar (on-demand)
End-to-end regulatory CDMO solutions: development, manufacturing, and approval
Navigating the journey from drug development to market can feel like a maze, with each step...
techs looking at screen - ACHIEV
White paper
Seamless commercial tech transfers in OSD manufacturing
Remember our insightful webinar on Commercial tech transfers in OSD manufacturing? If you missed it,...
Presentation (on-demand)
Challenging your AAV productivity and packaging efficiencies through a validated platform
AAV transient and stable cell line platforms represent a leap into next-generation technologies that...
CDMO Notes Blog post
Using bespoke downstream processing strategies for the purification of complex novel protein-based...
Discover how Lonza's innovative downstream processing strategies can help you overcome the...
Webinar (on-demand)
Commercial Tech Transfers in OSD Manufacturing
This webinar explores the critical aspects of manufacturing commercial tech transfers for the...
Two men working in the lab micro pipetting.
R&D Blog post
In-use stability and compatibility of Biologics – How to safely administer an effective medicinal...
Ensuring that patients receive the highest quality treatment under the best possible conditions is a...
Bispecific vial hand
Webinar (on-demand)
Rapid delivery of toxicological study material: The new critical path for accelerating...
With ever-increasing speed from DNA to IND, the window for toxicological data generation is becoming...
Lonza_Bend_InhalationLab.010
White paper
The Role of Excipients in Inhaled Biologics
The field of inhaled biologics is rapidly expanding, with both dry and liquid formulations of...
CDMO Notes Blog post
Accelerated Tox Offerings: A Recipe for Streamlining IND Applications
Accelerating the timeline to tox material can significantly enhance the drug development process,...
Webinar (on-demand)
Lonza Drug Product OPCU Capacity Update
Explore Lonza's end-to-end Drug Product capabilities along the full life cycle, seamlessly...
Lonza Bend Solid Form Services
Webinar (on-demand)
De-Risking Early Phase Micronization with Integrated Solid Form Selection
Achieving the right particle size for respiratory drug delivery is crucial, and jet milling is a...